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Ottawa, Canada; Houston, Texas; and Chicago, IllinoisIn 1956, Blankerhorn and Gall (1) proposed the term
myocarditis for inﬂammatory heart muscle disease, and
myocardiosis for other heart muscle diseases. A year thereafter,
Brigden (2) deﬁned cardiomyopathies as uncommon, non-
coronary heart muscle diseases. Subsequently, Goodwin and
Oakley (3) deﬁned cardiomyopathies as myocardial diseases of
unknown origin, and proposed categorization of the disor-
ders as dilated (DCM), hypertrophic (HCM), and restrictive
(or obliterative) (RCM) cardiomyopathies. In 1980, the
World Health Organization (WHO) and International
Society and Federation of Cardiology (ISFC) established the
deﬁnition of cardiomyopathies as myocardial diseases of
unknown etiology, reﬂecting the general lack of informationSee page 2073about the mechanism(s) of disease (4). Although WHO-
ISFC retained the 3 morphological types of cardiomyopa-
thies proposed by Goodwin and Oakley, it also introduced
the term speciﬁc heart muscle disease, where the cause of
myocardial dysfunction was known. The WHO-ISFC
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deﬁned cardiomyopathy as the diseases of myocardium
associated with myocardial dysfunction. Two additional
classes, arrhythmogenic right ventricular cardiomyopathy
(ARVC) and unclassiﬁed cardiomyopathy, were introduced
during the revision, and the category of the speciﬁc heart
muscle disease was excluded (5). The ISFC changed its name
to the World Heart Federation (WHF) in 1998 (6), and did
not indulge in further revision of the recommendations for
either diagnosis or management of cardiomyopathies.
A substantial increase in the knowledge of the genetic
basis of cardiomyopathy has occurred, and noninvasive
phenotypic characterization has become signiﬁcantly more
sophisticated. Therefore, the American Heart Association
(AHA) (7) and the European Society of Cardiology (ESC)
(8) in the last decade have proposed revisions to the classi-
ﬁcation of cardiomyopathic disorders. Whereas both sys-
tems have substantial similarities and have made important
recommendations, the former has described cardiomyopa-
thies starting from the genetic basis of the etiology followed
by the phenotypic description of myocardial involvement.
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2047original morphofunctional categories with further subclas-
siﬁcation into genetic (familial) and nongenetic (nonfa-
milial) groups. Both classiﬁcations continue to exclude
speciﬁc heart muscle disease (resulting from coronary,
hypertensive, valvular, and congenital heart disease) from
consideration as a cardiomyopathic disorder.
There is no denying the fact that most cardiomyopathies
are genetic diseases, which in the real life are brought to
clinical attention (and diagnosed and managed) based on
a phenotypic diagnosis. More than 60 disease genes have
been identiﬁed to date (9); genes such as MYBPC3 may be
associated with different phenotypes (HCM, RCM, DCM),
and genes such asDYSmay cause a unique phenotype (DCM
only). The penetrance of the genetic mutation is variable, and
phenotypic manifestations are often age dependent. Most
genetic cardiomyopathies are inherited as autosomal domi-
nant traits, with a minority of families demonstrating auto-
somal recessive, X-linked recessive or dominant (rare), and
matrilineal inheritance. Cascade family screening and follow-
up have become mandatory (10). It has become necessary for
a more descriptive nosology to be developed that may
encompass either all attributes of the individual patient
cardiomyopathy or allow a common platform for collaborative
research efforts. A number of experts, including clinical
cardiologists, heart failure–transplantation physicians, ge-
neticists, and cardiovascular imagers, have proposed
a systematic nomenclature endorsed by the WHF Scientiﬁc
Committee. The proposed classiﬁcation is a descriptive
presentation of the cardiomyopathic process, which is ﬂexibly
modiﬁable and expandable. This nosology is inspired from the
TNM staging of tumors and is being simultaneously pub-
lished by the Journal of the American College of Cardiology and
the ofﬁcial journal of the WHF, Global Heart.
The AHA (2006) classiﬁcation. In 2006, a scientiﬁc state-
ment from the AHA redeﬁned cardiomyopathy as a het-
erogeneous group of diseases of myocardium associated with
mechanical and/or electrical dysfunction, which usually (but
not invariably) exhibit inappropriate ventricular hyper-
trophy or dilation, due to a variety of causes that frequently
are genetic (7). The etiology of some cardiomyopathies
originally classiﬁed as idiopathic or primary cardiomyop-
athy, or heart muscle disease of unknown cause had
become known, and therefore, such entities could not be
described as idiopathic any further. In the AHA 2006
deﬁnition, primary cardiomyopathy referred solely or pre-
dominantly to the involvement of heart; the primary
cardiomyopathy designation in the new deﬁnition did not
mean diseases of myocardium associated with myocardial
dysfunction as intended in the 1996 WHO-ISFC classiﬁ-
cation. The secondary cardiomyopathy in the AHA classi-
ﬁcation was applicable when the myocardial dysfunction
was part of a systemic process. The proposed classiﬁcation
is reproduced in Figure 1A. Myocardial dysfunction
resulting from or associated with coronary, hypertensive,
valvular, or congenital heart disease was not classiﬁed ascardiomyopathy. The WHF writing group applauds the
efforts of the AHA 2006 writing committee for the ﬁrst
genuine attempt to introduce a genetic basis of classiﬁca-
tion of cardiomyopathies.
The ESC (2008) classiﬁcation. Although recognizing
the necessity for identifying the causative genetic defect as
proposed by AHA (2006) nomenclature, the ESC classiﬁ-
cation emphasized that because the morphofunctional
phenotype was the basis of the management of cardiomy-
opathy, it must also continue to be the basis of classiﬁcation.
ESC panelists emphasized that some of the so-called primary
cardiomyopathies may be associated with extracardiac mani-
festations and may not justify the primary cardiomyopathy
designation. Similarly, so-called secondary cardiomyopathy
may occasionally involve the heart predominantly and defy
designation as secondary cardiomyopathy (8). In the ESC
classiﬁcation, cardiomyopathy was deﬁned as a myocardial
disorder in which the heart muscle is structurally and
functionally abnormal. Cardiomyopathy was grouped into
morphofunctional phenotypes relevant for day-to-day clinical
practice. These included dilated, hypertrophic, restrictive, and
arrhythmogenic right ventricular cardiomyopathy and
unclassiﬁed variety. Each of these types was further divided
into familial genetic and nonfamilial, nongenetic forms. Ion
channelopathies, a genetic subtype included in the AHA
classiﬁcation of primary cardiomyopathy, was not accepted as
cardiomyopathy in this classiﬁcation because genes encoding
for ion channels might not result in morphofunctional
phenotypes. However, similar to the AHA classiﬁcation,
myocardial dysfunction secondary to coronary, hypertensive,
valvular, or congenital heart disease was not considered as
cardiomyopathy. In the ESC 2008 classiﬁcation, the cardio-
myopathy was deﬁned as familial when present in more than
1member of the family. A genetic cardiomyopathy is sporadic
when the causative mutation is de novo, namely occurring for
the ﬁrst time and exclusively in the affected family member.
The proposed classiﬁcation is reproduced in Figure 1B.
Theproposedphenotype-genotype-based (2013) classiﬁcation
endorsed by WHF. In the last 10 years, knowledge of the
genetics of cardiomyopathies has evolved exponentially, and at
least 60 disease genes have been either conﬁrmed or suspected as
candidate genes (Table 1). The genetic heterogeneity is estab-
lished, and the implementation of next-generation sequencing is
further expected to increase the existing pool of knowledge. It is
conceivable that although the diagnosis based on phenotype is
still clinically useful, it is not sufﬁcient to stratify prognosis in
cardiomyopathies caused by mutations in different genes and
that grouping cardiomyopathies per disease gene provides the
basis for implementation of disease-speciﬁc research. The major
clinical decisions (such as implantable cardioverter-deﬁbrillator
[ICD] implantation) are still based on functional (such as left
ventricular [LV] ejection fraction [LVEF] in DCM) or
morphological (such as maximal LV wall thickness in HCM)
criteria regardless of the intrinsic disease risk related to the type
Figure 1 Current Classiﬁcations Of Cardiomyopathies
The 2006 American Heart Association classiﬁcation proposes genetics-based classiﬁcation (A). On the other hand, the 2008 European Society of Cardiology classiﬁcation
suggests ﬁrst the morphofunctional phenotype and then the addition of inheritance information (B). ARVC/D ¼ arrhythmogenic right ventricular cardiomyopathy/dysplasia;
CVPT ¼ catecholaminergic polymorphic ventricular tachycardia; DCM ¼ dilated cardiomyopathy; HCM ¼ hypertrophic cardiomyopathy; LVNC ¼ left ventricular noncompaction;
LQTS ¼ long QT syndrome; RCM ¼ restrictive cardiomyopathy; SQTS ¼ short QT syndrome; SUNDS ¼ sudden unexplained nocturnal death syndrome.
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2048of causative gene mutation (11–13). Troponinopathies may not
be associated with severe LV wall thickness but carry a high
arrhythmogenic potential (14). Similarly, laminopathies may not
necessarily demonstrate severe LV dysfunction when their
arrhythmogenic risk ﬁrst manifests (15). On the other hand,
dystrophinopathies may display dramatically enlarged and dys-
functioning LV but are less susceptible to the risk of malignant
arrhythmias; such patients, however, can deteriorate rather
precipitously with as small an insult as a ﬂu episode and deserve
timely assistance (16). Based on the underlying gene mutations,
numerous new terms (such as desmosomalopathies [17], cytoske-
letalopathies [18], sarcomyopathies [18], channelopathies [19], car-
diodystrophinopathies [16], or cardiolaminopathies [20]), inspired
by the general practice of myologists (such as zaspopathies [21],
myotilinopathies [22], dystrophinopathies [23], alphaB-crystal-
linopathies [21], desminopathies [24], or caveolinopathies [25]), arebeing proposed that are likely to cloud the cardiomyopathy
description, and it has become important that a uniform
nomenclature be developed.
By the classiﬁcation herein proposed, the cardiomyopa-
thies are described as disorders characterized by morpholog-
ically and functionally abnormal myocardium in the absence
of any other disease that is sufﬁcient, by itself, to cause
the observed phenotype. In this nosology, although the
conventional phenotypic subtype of the cardiomyopathy (e.g.,
dilated, hypertrophic) continues to provide the elements for
the basic classiﬁcation, a genotype-based assessment dictates
the diagnostic work-up and treatment decisions in probands
and relatives, as well as the follow-up plans. Figure 2 shows an
example of the impact of an accurate genetic diagnosis on 2
patients with a similar phenotype at presentation. Once the
genetic cause of the cardiomyopathy has been deﬁned, the
Figure 2 Importance of Genetic Information in DCM Patients
Two pedigrees with probands (arrows) demonstrate similar DCM phenotypes at
the onset of disease. The identiﬁcation of the causative genes and mutations
underscores the importance of the genetic diagnosis on the management of the 2
families (A,B). In family A, the identiﬁcation of a mutation in the Emerin (EMD)
gene provides information about the genetic status of the offspring (C). The son of
the proband is obligate negative because a male cannot transmit an X-linked
defect to his son. On the other hand, the daughters of affected males in X-linked
diseases are obligate carriers of the paternal mutations. (D) In family B, the
identiﬁcation of a mutation in the Lamin A/C (LMNA) gene provides evidence that
offspring can inherit the mutation with 50% probability for each pregnancy (D). In
this family in the right panel, both children inherited the paternal mutation (þ).
Pedigree symbols for this and subsequent ﬁgures: circles for females, squares for
males, diagonal lines represent deceased, solid-ﬁlled symbols denote cardiomy-
opathy, shaded symbols for uncertain cardiac phenotype, dotted circles denotes
healthy carriers. AD ¼ autosomal dominant; AVB ¼ atrioventricular block; DCM ¼
dilated cardiomyopathy; ECG ¼ electrocardiogram; EF ¼ ejection fraction;
LVEDD ¼ left ventricular end-diastolic dimension; NYHA ¼ New York Heart Asso-
ciation; PM ¼ pacemaker; sCPK ¼ serum creatine phosphokinase; SD ¼ sudden
death; TAPSE ¼ tricuspid annular plane systolic excursion; XLR ¼ X-linked
recessive.
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carriers that will eventually develop the phenotype over the
ensuing years (Fig. 3) (10). Avoidance of competitive sport
activity and tailored monitoring with early medical treatment
may favorably inﬂuence the natural history of the disease and
the development of the manifest phenotype, as well as the risk
of life-threatening arrhythmias. Identiﬁcation of genetic
diseases may also help subjects and alert physicians to refrain
from the use of injurious agents. For instance, agents trig-
gering malignant hyperthermia (succinyl choline) or volatileanesthetics (halothane and isoﬂurane) are to be avoided
in emerinopathies and laminopathies causing muscular
dystrophy (26). Statins should be administered with caution
in patients with genetic cardiomyopathies with possible
involvement of the skeletal muscle, even when markers
of myopathy are negative (27). Patients with disorders of
the respiratory chain may need surgeries in their long-term
care, but anesthetics may interfere with metabolism and
may trigger unexpected complications (28). Patients with
mitochondrial cardiomyopathy and epilepsy should not
receive valproate because it could cause pseudoatrophy of
brain (29). Common indications for heart transplantation
(HTx) in patients with end-stage cardiomyopathy should take
into account the speciﬁc diagnosis; conditions such as Danon
disease in males, or other comorbidities such as mental
retardation, are a matter of debate about indications for HTx
(30). Finally, genotype-based diagnoses can be pooled in large
international databases for future clinical trials and validation
of novel management strategies.
The MOGE(S) Nomenclature System
While waiting for the complete knowledge that may even-
tually support a genetic classiﬁcation of cardiomyopathies
(also the ultimate intent of the AHA and ESC classiﬁca-
tions), we propose a nosology that addresses 5 simple
attributes of a cardiomyopathic disorder, including mor-
phofunctional characteristic (M), organ involvement (O),
genetic or familial inheritance pattern (G), and an explicit
etiological annotation (E) with details of genetic defect or
underlying disease/cause; information about the functional
status (S) using the American College of Cardiology/
American Heart Association (ACC/AHA) (A to D) stage
and New York Heart Association (NYHA) (I to IV) func-
tional classes may also be added. The addition of (S) has
been left optional, and should be used at the discretion of the
physician. With the description of 5 attributes, the classiﬁ-
cation system is designated as MOGE(S).
 The morphofunctional (M) notation provides a
descriptive diagnosis of the phenotype (MD ¼ dilated
cardiomyopathy; MH ¼ hypertrophic cardiomy-
opathy; MA ¼ arrhythmogenic right ventricular (RV)
cardiomyopathy; MR ¼ restrictive cardiomyopathy;
MLVNC ¼ LV noncompaction). Description of
combined/overlapping phenotypes (MDþR or MHþD)
is easy to document, and disease-speciﬁc clinical
markers can also be added, such as atrioventricular
block (AVB), Wolff-Parkinson-White syndrome
(WPW), epsilon wave (MD[AVB], MH[WPW], MA
[εwave]). Although not likely, myocardial dysfunction
with a nonspeciﬁc phenotype may be mentioned
(MNS). Early involvement or no involvement in
a mutation carrier with affected family members should
be documented as either with early imaging markers
(ME[H] or ME[D]) or unaffected (M0) with the expected
cardiac phenotype in brackets. When the information
Table 1 List of Nuclear Genes Associated to Date With Cardiomyopathies
Nuclear Genes
MIM*
Gene Protein or Syndrome HCM RCM DCM ARVC LVNC
Clinical Traits
(Red Flags)
Phenotypes/Diseases Caused by
Mutations of the Same Gene Inheritance
ABCC9 601439 ATP-binding cassette, subfamily C, member 9 X Hypertricosis Cantu syndrome AD
ABLIM1 602330 Limatin (actin-binding LIM domain protein) X LVNC AD
ACTC1 102540 Cardiac actin alpha X X X X Nemaline myopathy AD
ACTN2 102573 Alpha-actinin 2 X X AD
ALMS1 606844 ALMS1-C X (70% DCM) Alstrom syndrome AR
ANO5 608662 Anoctamin 5 X Dysphagia Limb girdle muscular dystrophy,
Gnathodiaphyseal dysplasia, Miyoshi
muscular dystrophy 3
AR
ANKRD1 609599 Ankyrin repeat domain-containing protein 1 X AD
BAG3 603883 BCL2-associated athanogene X X BAG3-related myoﬁbrillar myopathy, CRYAB-
related myoﬁbrillar myopathy, fatal
infantile hypertrophy
AD
CALR3 611414 Calretinin 3 X AD
CASQ2 114251 Calsequestrin 2 X X AD
CAV3 601253 Caveolin3 X X sCPK elevated; long QT syndrome-9; muscular
dystrophy, limb-girdle; myopathy, distal,
Tateyama type; rippling muscle disease
CRYAB 123590 Alpha B crystallin X X X Cataract Posterior polar cataract AD
CSRP3 600824 Cysteine- and glycine-rich protein 3 X X AD
DES 125660 Desmin X X X AVB, [sCPK Des-related myoﬁbrillar myopathy,
neurogenic scapuloperoneal syndrome,
Kaeser type
AD
DMD 300377 Dystrophin X >sCPK/myopathy Duchenne muscular dystrophy, Becker
muscle dystrophy
X-linked
recessive
DMPK 605377 Dystrophia myotonica protein kinase gene X AVB (Dystrophia myotonica type 1) or Steinert’s
disease
AD
DOLK 610746 Dolichol kinase X Myopathy, possible
ichthyosiform
dermatitis
Congenital disorder of glycosylation, type Im AR
DSC2 125645 Desmocollin 2 X X With and without mild palmoplantar
keratoderma and woolly hair
AD
DSG2 125671 Desmoglein 2 X X AD
DSP 125647 Desmoplakin X X Lethal acantholytic epidermolysis bullosa,
keratosis palmoplantaris striata II, skin
fragility–woolly hair syndrome
AD
DTNA 601239 Dystrobrevin alpha X With or without congenital heart defects AD
EMD 300384 Emerin X AVB, myopathy,
[sCPK
EDMD1, X-linked X-linked
recessive
EYA4 603550 Eyes absent 4 X Deafness Deafness, autosomal dominant AD
FHL1 300163 Four-and-a-half LIM domains 1 X X Myopathy EMDM 6, X-linked, myopathy, reducing body,
childhood-onset and severe early-onset,
myopathy with postural muscle atrophy,
scapuloperoneal myopathy, X-linked
dominant
X-linked
recessive,
X-linked
dominant
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Table 1 Continued
Nuclear Genes
MIM*
Gene Protein or Syndrome HCM RCM DCM ARVC LVNC
Clinical Traits
(Red Flags)
Phenotypes/Diseases Caused by
Mutations of the Same Gene Inheritance
GATAD1 614518 GATA zinc ﬁnger domain containing protein 1 X AD
ILK 602366 Integrin-linked kinase X AD
JUP (DP3) 173325 Plakoglobin, desmoplakin III X X Naxos traits AD, AR
LMNA 150330 Lamin A/C X X AVB, possible [sCPK DCM with conduction disease plus
11 additional phenotypes
AD
LAMA4 600133 Laminin alpha 4 X AD
LDB3 605906 LIM domain- binding 3 X X X LVNC,
hypertrabeculation;
possible [sCPK
ZASP-related
myoﬁbrillar
myopathy
AD
MYBPC3 600958 Myosin-binding protein C X X X AD
MYH6 160710 Alpha-myosin heavy chain 6 X X Atrial septal defect, sick sinus syndrome AD
MYH7 160760 Beta-myosin heavy chain 7 X X X X Possible [sCPK Laing distal myopathy; myosin storage
myopathy; scapuloperoneal syndrome,
myopathic type
AD
MYL2 160781 Myosin light chain 2 X AD
MYL3 160790 Myosin light chain 3 X X AD, AR
MYOZ1 605603 Myozenin 1 X X AD
MYOZ2 605602 Myozenin 2 X AD
MYPN 608517 Myopalladin X AD
NEBL 605491 Nebulette X AD
NKX2-5 600584 NK2 homeobox 5; cardiac-speciﬁc homeobox1 X Possible conduction
system disease
AD
PDLIM3 605889 PDZ LIM domain protein 3 X AD
PLN 172405 Phospholamban X AR
PKP2 602861 Plakophilin 2 X X AD
PSEN1 104311 Presenilin 1 X Acne inversa, familial, 3, Alzheimer disease,
type 3, Frontotemporal dementia, Pick
disease
AD
PSEN2 600759 Presenilin 2 X Alzheimer disease AD
RBM20 613171 RNA-binding protein 20 X AD
RYR2 180902 Ryanodine receptor 2 X Ventricular tachycardia, catecholaminergic
polymorphic 1
AD
SCN5A 600163 Sodium channel, voltage gated, type V, alpha
subunit
X Possible LQT or
Brugada Syndrome
LQT3, Brugada 1, AF, SSS, familial VF AD
SGCD 601411 Delta-sarcoglycan X Limb-girdle muscular dystrophy AD
SYNE1 608441 Nesprin 1, synaptic nuclear envelop protein 1 X EMD4, AD; Spinocerebellar ataxia, autosomal
recessive
AD
TCAP 604488 Titin-cap; telethonin X X [sCPK Muscular dystrophy, limb-girdle, type 2G AD
TCF21 603306 Transcription factor 21, epicardin X Hearing loss Hearing loss AD
TGFB3 190230 Transforming growth factor beta-3 X X AD
TMEM43 612048 Transmembrane domain 43 X X Emery-Dreifuss muscular dystrophy, AD AD
TMPO 188380 Thymopoietin X AD
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2052about the morphofunctional cardiac phenotype is not
available (for example, in deceased relatives), the
description is MNA[H].
 The organ involvement (O) is documented as heart
only (OH) or involvement of other organs/systems as
below. The extracardiac involvement may be described
by organ/system notations, such as skeletal muscle
(OHþM), auditory system (OHþA), kidney (OHþK),
nervous system (OHþN), liver (OHþL), gastrointestinal
system (OHþG), cutaneous (OHþC), ocular system
(OHþO), or OHþMR for mental retardation. Involve-
ment of other organs may represent the systemic
disease. Healthy mutation carriers can be described as
(O0), because the heart is not yet involved.
 The genetic or familial inheritance (G) provides
information about autosomal dominant (GAD), autosomal
recessive (GAR), X-linked (GXL), X-linked recessive
(GXLR),X-linked dominant (GXLD), ormatrilineal (GM)
transmission. GXL could also be used without recessive
or dominant speciﬁcation for conditions when an
X-linked inheritance is strongly suspected on the basis
of pedigree and family screening but is not yet sup-
ported by results of genetic testing and should be
clariﬁed in the E notation. Sporadic (GS) indicates only
a nonfamilial disease or a disease present in one family
member when information or data on other family
members are not (and will not be) available. Sporadic
(GS) notation is also applied in cases with possible
de novo mutation not yet identiﬁed. GN indicates
negative family history, and GU indicates unknown
family history. G0 indicates that family history has not
been investigated so far.
 The etiological annotation (E) adds to the descrip-
tion of the underlying cause. For instance, genetic (EG)
etiology can be described by the speciﬁc disease gene
and mutation(s) such as in the case of HCM (EG-
MYH7[p. Arg403Glu]), or familial amyloidosis (EA-TTR
[p.Val122Ile]), and so on. Etiological speciﬁcation may
include: noncarrier (EG-Neg) when the disease gene
tested negative; obligate carrier (EG-OC); obligate
noncarrier (EG-ONC); presence of more than 1 muta-
tion (or complex genetic defects, EG-C wherein all
genetic information should be documented); genetic
test not available yet, but the family data clearly indi-
cate a genetic disease or the test is ongoing (EG-NA);
genetically orphan patients after completion of the
screening of all known disease genes in familial disease
(EG-N); or genetic testing is not done or not feasible for
any reason (EG-0). All above may facilitate description
of mutations that do not segregate with the phenotype
or incomplete genotyping. Please see speciﬁc examples
in the individual cardiomyopathy sections in the
following text and in Figures 2 to 10.
On the other hand, the nongenetic etiology can be
described as viral (V) adding the virus (e.g., Coxsackie
Figure 3 Genotype, DCM, and the Natural History
In 1994, a patient underwent heart transplantation (HTx) (arrow) for end-stage
DCM associated with AVB. The patient had received a pacemaker 4 years earlier.
His mother had died of heart failure due to DCM, and AVB was treated with
pacemaker implantation. In 2001, the LMNA gene was discovered and was found
to be the etiology of cardiomyopathy in this family with DCM and conduction
disease. The cascade family screening further uncovered 2 sons of the proband
and the daughter of his sister as the healthy mutation carriers. In 2004, the sister
of the proband underwent HTx for DCM and AVB, and in 2012, the oldest son of
the proband was diagnosed with early DCM. This 18-year-long follow-up highlights
the importance of genetic characterization in cardiomyopathic disorders. Abbrevi-
ations as in Figure 2.
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2053B3 virus [CB3], human cytomegalovirus [HCMV],
Epstein-Barr virus [EBV]) as (EV-HCMV), (EV-CB3) or
(EV-EBV). Similarly, infectious nonviral disease can be
described as (EI) with further speciﬁcation of the
infectious agent when possible. Myocarditis can be
described as (EM) when the myocarditis is the proven
cause of the myocardial disease; speciﬁcation about
sarcoidosis or nonviral or noninfectious giant cell
myocarditis should be added (EM-sarcoidosis). Autoim-
mune etiology, either suspected or proven, can be added
(EAI-S) or (EAI-P), respectively, after having excluded
genetic and viral or toxic causes, especially in patients in
whom a speciﬁc etiology may inﬂuence treatment. In
the E annotation, nongenetic amyloidosis (EA-K) or
(EA-L) or (EA-SAAA) should be described with kappa,lamda, serum amyloid A, or other protein character-
ization. Toxic cardiomyopathies, either endogenous
such as pheochromocytoma-related cardiomyopathy, or
drug-induced cardiomyopathy, are described (ET-Pheo-
chromocytoma or ET-Chloroquine). The eosinophilic Loefﬂer
endomyocarditis can be described according to the
cause as either being idiopathic or a part of myelopro-
liferative disorder associated with the somatic chro-
mosomal rearrangement of PDGFRa or PDGFRb
genes that generate a fusion gene encoding constitu-
tively active PDGFR tyrosine kinases. TheE annotation
will be modiﬁed in the future as various conditions
are excluded from the category of cardiomyopathic
disorders or as the newer entities are recognized.
 It is proposed that Heart Failure Stage (S) may be
provided pertaining to ACC/AHA stage (A to D)
and NYHA functional class (I to IV) if deemed
necessary. For instance, stage A disease with functional
class I can be written as (SA-I) or stage C disease in
functional class II symptomatic subjects can be referred
to as (SC-II). Addition of the ﬁfth descriptor (S) is
optional, but may come in handy for the description
of early cardiomyopathy. Early cardiomyopathy is
a conditionwhere the clinical criteria for diagnosis of the
cardiomyopathy are not present, but genetic mutation
has been conﬁrmed and/or subclinical imaging evidence
of myocardial involvement is apparent. The imaging
alterations may include increased LV end-diastolic
diameter and reduced longitudinal strain with still
normal ejection fraction (EF) for DCM, or borderline
LV thickening for HCM. The ACC/AHA guidelines
include patients with a family history of cardiomyopathy
in stage A. Therefore, the MOGE(S) can take
advantage of the stage to describe individuals that show
early markers of disease but do not fulﬁll the diagnostic
criteria for the cardiomyopathy. In families with known
mutation, the diagnosis of early cardiomyopathies can
be further supported by the presence of the muta-
tion(s), whereas in genetically orphan familial cardio-
myopathies, only the early imaging markers of the
disease can be highlighted. This description could be
especially useful for sport worthiness that often requires
physicians to provide a deﬁnitive recommendation, and
(S) notation may allow the description of a gray diag-
nostic zone. Although criteria for early diagnosis of
cardiomyopathy are not systematically described, the
increasing family screening and monitoring have
revealed that the cardiomyopathies likely serve a long
pre-clinical or subclinical interval before the onset
of symptoms or the manifestation of the clinical
phenotype (31).
Table 2 shows the MOGE(S) system notations and
modeling. The alphabetical components are likely going to
change in parallel with new scientiﬁc discoveries. As
Figure 4 The MOGE(S) in a Family With HCM
The MOGE(S) system allows presentation of all essential clinical and genetic information in a family with HCM and complex genetics. The pedigree shows the affected
and nonaffected status of family members and the mutations identiﬁed in the family. The table (bottom) shows the application of the MOGE(S) system and the comprehensive
description of the genetic make-up and phenotype expression in the members of different generations of the family. Although 3 mutations have been identiﬁed in this family, the
HCM is inherited as autosomal dominant disease, and the mutation that occurs in all affected members is MYH7 p.R663H; other mutations may contribute to worsen the
phenotype but do not seem to cause, by themselves, HCM. In families demonstrating autosomal dominant inheritance, the segregation of the mutation from the phenotype is
necessary to avoid labeling of the carriers of nondeterministic gene variants as possible future patients, and to provide a correct interpretation of results in case of prenatal
diagnosis. Given the high prevalence of HCM in the general population (1:500), families carrying more than 1 mutation are not rare, and are expected to further increase
with next-generation sequencing (NGS), that allows sequencing of several common and rare genes in a large number of patients simultaneously. AF ¼ atrial ﬁbrillation;
ICD ¼ implantable cardioverter-deﬁbrillator; IVS ¼ Intervening sequence; other abbreviations as in Figure 2. Grey ﬁlled symbols: mild LVH.
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Figure 5
MOGE(S) in a Family With Mitochondrial Cardiomyopathy: Evolution of the Disease in Family and Clariﬁcation
of the Genetic Basis of Disease During Follow-Up
The pedigree illustrates the case of a young boy who was affected by mild mental retardation and bilateral coloboma. In 2007 he was ﬁrst diagnosed with HCM and
Wolff-Parkinson-White syndrome (WPW). His family history revealed the death of a maternal cousin at the age of 22 years for Duchenne muscular dystrophy (DMD). Based
on family history and pedigree, the ﬁrst hypothesis was an X-linked recessive disease, which was, however, unlikely because of the HCM phenotype, the WPW, and the mental
retardation. The DYS gene tested negative in the proband (both multiplex ligation-dependent probe ampliﬁcation [MLPA] and sequencing) as well as in the mother and maternal
grandmother whose sister was healthy carrier of DYS mutation and mother of the young man with DMD. LAMP2 was analyzed because of the HCM phenotype with WPW
and cognitive impairment, and tested negative. Sequencing of the mitochondrial DNA (mtDNA) demonstrated the MT-TL1 MELAS/LS A3243G mutation [tRNA Leu (UUR)],
heteroplasmic in all maternal relatives and in the boy. Endomyocardial biopsy was not performed. During the ensuing years, the patient showed worsening of HCM with evolution
of left ventricular (LV) dysfunction (LVEF ¼ 35%) and developed stroke-like episodes to result in death. The MOGE(S) system summarizes the clinical and genetic status of the
family in 2011 and the key clinical traits of the disease. LVH ¼ left ventricular hypertrophy; other abbreviations as in Figure 2.
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2055anticipated, the proposed nosology is modeled similarly to
the universally accepted TNM staging of tumors, which has
been consistently expanded and has allowed use ofa common language of clinical comprehension and utility
(32). In TNM staging, the T describes the size of carci-
noma and extent of local invasiveness, N stands for the
Figure 6 MOGE(S) in a Family With AFD
On the left side of the ﬁgure, the example of Anderson-Fabry disease (AFD) highlights the importance of family study and demonstrates how simple is it to suspect the disease
(left). The proband (arrow) was brought to medical attention for the clinical suspicion of HCM. The family history, however, revealed long-lasting maternal gastrointestinal
disturbances (common diseases causing such disorders had been excluded), a stroke in the maternal aunt, and renal failure in the maternal male cousin. Further screening of
the family uncovered cornea verticillata in the mother and angiokeratomas in the male cousin. The serial examination of urine samples in the proband showed intermittent
proteinuria, and the genetic testing conﬁrmed the diagnosis of AFD. The MOGE(S) ﬁgure only summarizes the last clinical and genetic status of the family. Individual VI:1 is an
obligate noncarrier, whereas individual I:1 (genetic test not performed) is an obligate carrier because the wife tested negative and both daughters carried the mutation. If the
genetic test were available in I:1, it would not have been necessary in the daughters because both are naturally obligate carriers. In the right half of the ﬁgure, from top to
bottom, the pathological features of AFD in endomyocardial biopsy are shown. (A) Hematoxylin and eosin stain shows a large number of vacuolated myocytes (glyco-
sphingolipids are extracted in formalin-ﬁxed, parafﬁn-embedded tissues); (B) the toluidine blue stain of the semi-thin sections from resin-embedded samples for electron
microscopy show characteristic intramyocyte accumulation of osmiophilic bodies of the storage material; and (C) the ultrastructural panel conﬁrms the typical lamellar and
dense osmiophilic bodies. Abbreviations as in Figures 2. Grey ﬁlled symbols: mild LVH.
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Figure 7 MOGE(S) in a Family With Danon Disease
The example of Danon disease caused by a mutation of the LAMP2 gene and the natural history of the disease in the family from 1986 to 2013; the family history of 27 years
is summarized in the table (bottom right). Although Danon disease in its typical presentation affects males (LAMP2 gene maps on the X chromosome) who show HCM,
myopathy, and mental retardation (see the table), the cardiac phenotype is expressed also in adult female carriers who do not show myopathy and mental retardation. The
II:3 male showed the typical phenotype; his sister who had 3 pregnancies and 3 prenatal diagnoses is now affected by cardiomyopathy. Her second pregnancy (a male fetus and
a positive genetic test) ended in a voluntary interruption, whereas the third pregnancy (female fetus and positive genetic testing) ended in a Cesarean section due to worsening
of ventricular arrhythmias during pregnancy. The girl is now well with normal electrocardiographic and echocardiographic features. The chromatogram shows the mutation
identiﬁed in the LAMP2 gene in I:2. Abbreviations as in Figure 2.
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2057status of lymph nodes, and M provides for the presence or
absence of metastases. There are additional descriptors; for
instance, the preﬁx y with T indicates that the cancer was
resected after neoadjuvant therapy, r indicates recurrence of
cancer, and m identiﬁes multifocal cancer. Similarly the
nodal status can be iD (isolated tumor cells), mic (micro-
metastatic, 0.2 to 2.0 mm), or mac (macrometastases, >2
mm). The clinical staging is designated as cTNM and the
pathological staging of cancer as pTNM.
In the MOGE(S) nomenclature, ion channelopathies are
not included, but can be incorporated if so needed in thefuture. The reason for the exclusion is that due to the high
prevalence of genetic variations in ion channel genes and
the ever-increasing genetic complexity of cardiomyopathy,
it cannot be excluded that few available reports of ion
channel mutations in patients with cardiomyopathy (in
the absence of screening of all other disease genes) may in
fact represent an incomplete genotyping. In a series of more
than 100 DCM patients in whom the SCN5A gene was
screened along with other genes, a single mutation was
identiﬁed in 1 patient who was also carrier of the PLN
mutation (33). The channelopathies are nosologically
Figure 8 MOGE(S) in RCM With Cardiac Desminopathy and Intramyocyte Storage of Desmin
Typical cardiac desminopathies with intramyocyte desmin accumulation are clinically characterized by RCM and AVB; the family history is presented in left panel and the
typical pathologic features of the myocardium in the right panel. Individual I:1 underwent heart transplantation (HTx), as did her son II:3. The other 2 affected sons died of heart
failure after diagnosis of RCM and pacemaker implantation. After transplantation II:3 married the unrelated II:4 (shown in blue letters in the MOGE, 2013 table) who also
underwent HTx for DCM. II:4 had undergone HTx without family screening with a presumptive diagnosis of post-myocarditic DCM. However, her heart excised at transplantation
did not show features of myocarditis, and the viral genome search was negative. The couple (II:3 and II:4) had a boy (III:1) in which the paternal DES mutation was excluded.
However, in case the viral etiology of the DCM was wrong and the mother had a genetic DCM, the genetic status of the boy (although DES mutation is ruled out) remains
incomplete, and the risk of developing DCM is unknown. The right panel shows (A) hematoxylin and eosin–stained myocardial samples in desminopathy. The eosinophilic
bodies correspond to the accumulation of desmin, and myoﬁbrillar disarray is present. (B) Anti-desmin immunostaining supports the diagnosis but remains nonconclusive in
light microscopy study due to the variable orientation of myocytes in small EMB samples with procedure-related contraction bands. (C) Electron microscopy study is the gold
standard for the pathological diagnosis. Abbreviations as in Figure 2.
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2058well-deﬁned arrhythmogenic disorders (34) without LV
remodeling and with clinical needs that differ from those of
cardiomyopathies. Giving the large spectrum of electricalphenotypes associated with mutations of ion channel genes,
this group of diseases likely deserves a speciﬁc and inde-
pendent nomenclature.
A B
Figure 9 MOGE(S) in Dilated Cardiac Dystrophinopathy
The ﬁgure presents 3 diagnostic steps in a family with X-linked recessive DCM caused by deletion mutation of the Dystrophin gene. The proband showed an apparently sporadic
DCM with severely dilated left ventricle and decreased EF; the presence of increased sCPK suggested the possibility of a Dystrophin defect. The MLPA demonstrated an in-frame
deletion of exons 45 to 48. The noncarrier sister at her ﬁrst pregnancy asked about private umbilical blood cord preservation for future stem cell (SC) transplantation in the
affected brother. This request is increasing in Dystrophin families and, at present, regulatory bodies and scientiﬁc societies in different countries do not provide uniform
recommendations. We realize that a deﬁnite donor cell engraftment is not yet proven, and such a request should only be considered in consultation with SC transplantation
experts and specialized centers; private SC preservation with costs covered by the family is feasible. The family study documented the carrier status of the mother and of 1 of
the sisters (II:3). Bottom: the myocardial pathology shows that the Dystrophin defect is associated with decreased expression of the protein (B) as compared to abundant
expression (A) in a normal heart. A represents an endomyocardial biopsy specimen obtained from a donor heart before transplantation. Abbreviations as in Figure 2.
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2059The MOGE(S) nomenclature in the diagnostic work-up
of cardiomyopathies. It is expected that the clinical and
imaging characterization of the phenotype (M) would beroutinely deﬁned on morphological (dilated, hypertrophic,
LV noncompaction [LVNC]) and morphofunctional (re-
strictive, arrhythmogenic) traits, and the second descriptor
Figure 10 MOGE(S) in Barth Syndrome
The ﬁgure shows the case of a boy who demonstrated a severe and rapidly fatal neonatal dilated cardiomyopathy. The family history was negative: both parents were
healthy, and there were no relatives affected by cardiac diseases. The presence of LVNC suggested the possibility of Barth syndrome. The genetic testing showed
a hemizygous mutation in the G.4.5 gene encoding the nuclear mitochondrial protein tafazzin. The mutation was inherited from the healthy mother whose clinical screening
demonstrated a normal heart. At the second pregnancy, the prenatal diagnosis demonstrated a male fetus carrier of the mutation. The pregnancy was interrupted. At the
third pregnancy, the prenatal diagnosis showed the male fetus a noncarrier of the mutation. The pregnancy was successful, and the boy is healthy. The mother did not show
cardiac problems during or after the 3 pregnancies. Abbreviations as in Figure 2.
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whether the heart is the only affected organ or other organs/
systems are involved (Table 2). The disease may be systemic
and the involvement of the heart a part of general disease
process. This simple deﬁnition of the involvement of the
heart only, of the heart as a component of systemic disease
process, and the involvement of other organs provides useful
clinically discriminatory information. The ﬁrst combination
of (M) and (O) can offer preliminary diagnostic clues. For
instance, MH OHþSMþMR suggests the possibility of HCM
in either Danon or mitochondrial DNA–related disease;
when additional details are available, such as MH[WPW] OH,
a mutation of PRKAG2 might be suspected. Similar clues
could be available for dilated cardiolaminopathy MD[AVB]
OH, dilated cardiodystrophinopathy MD[[sCPK] OHþM, orrestrictive desminopathy MR[AVB] OHþM and underscore
the importance of identifying clinical indicators (“red ﬂags”)
in the MOGE(S) nomenclature (35).
Data from family pedigrees, including investigation for
the family history and the pattern of inheritance (G), add
valuable leads for complete characterization of the cardio-
myopathy. For example, a restrictive cardiomyopathy with
autosomal dominant inheritance, but without conduction
disease and involvement of other organ systems, suggests
troponinopathy (MR OH GAD). Information about G may
help discriminate similar phenotypes: (MH[WPW] OH GAD)
might suggest an HCM associated with PRKAG2 muta-
tion, whereas (MH[WPW] OHþMþMR GXL) suggests Danon
disease, or (MH[WPW] OHþMþN GM) mitochondrial
DNA–related cardiomyopathy. The etiological annotation
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2061(E) provides a descriptive analysis of the genetic defect
and/or underlying disease. For nongenetic and nonfamilial
cardiomyopathy, the E annotation may include other
etiologies.
Although it may seem a bit complex in the beginning,
this nomenclature does provide an articulated conﬁguration
that is able to transmit all essential information for every
cardiomyopathy type, patient, and family; a genetic tree
and reference to family members per generation may be
appended when needed (Fig. 4). An easy web application
(app) for MOGE(S) nomeclature can be accessed from
mobile phones and other devices (http://moges.biomeris.
com). The app becomes handy for correct notation at least
in the initial stages. The abbreviations applied here (such as
AVB or WPW) are consistent with terminology systems
such as Systematized Nomenclature of Medicine
(SNOMED) (36) or SNOMED CT (SNOMED Clinical
Terms) (37) and in the International Classiﬁcation of
Diseases (ICD) (38). The proposed nomenclature reﬂects the
diagnostic work-up of cardiomyopathies for evaluation of the
phenotype, implementation of family screening strategies for
diagnosis and prevention, and results of genetic testing in the
Sanger and post-Sanger era.Table 2 The MOGE(S) Nomenclature: Some Common Examples Are
M
Morphofunctional
Phenotype*
O
Organ/System
Involvementy
G
Geneticz
(D) Dilated
(H) Hypertrophic
(R) Restrictive
(A) ARVC
(NC) LVNC
Overlapping (HþR),
(DþA), (NCþH),
(HþD), (DþNC) or
more complex
combinations
such as
(HþRþNC)
(E) Early, with type in
parentheses
(NS) Nonspeciﬁc
phenotype
(NA) Information not
available
(0) Unaffected
(H) Heart
(M) Muscle, skeletal
(N) Nervous
(C) Cutaneous
(E) Eye
(A) Auditory
(K) Kidney
(G) Gastrointestinal
(S) Skeletal
(0) Absence of organ/
system
involvement, e.g., in
family
members who are
healthy mutation
carriers; the mutation
is speciﬁed in E and
inheritance in G
(N) Family history negative
(U) Family history unknown
(AD) Autosomal dominant
(AR) Autosomal recessive
(XLR) X-linked recessive
(XLD) X-linked dominant
(XL) X-linked
(M) Matrilineal
(DN) De novo
(0) Family history
not investigated
(G) Ge
Indi
neg
(OC) O
(ONC)
(DN) D
(C) Co
(pro
(Neg)
mut
(NA) G
(N) Ge
(0) No
info
Geneti
hem
Nonge
(M) My
(V) Vira
hea
(AI) Au
(AI-S
(A) Am
A-K;
(I) Infe
(T) Tox
(Eo) H
MD, MH, MR, MA, MNC,
M0, MHþR, MDþA
OH, OM, OK, OC GN, GU, GAD, GAR, GXLR,
GXLD, GXD, GM, GDN
EG-M
EV-H
*The morphofunctional phenotype description (M) may contain more information using standard a
LQT ¼ prolongation of the QT interval; AF ¼ atrial ﬁbrillation; YR ¼ low electrocardiogram voltages; YP
expanded for the involvement of M ¼ skeletal muscle, O ¼ ocular system, A ¼ auditory system, K ¼
comorbidities, including MR ¼mental retardation. zGenetic (G) describes the available information about
unknown, and if genetic testing has not been performed or was negative for the mutation/mutations iden
the speciﬁc disease gene and mutation, as well as description of nongenetic etiology. kThe functional a
ACC/AHA ¼ American College of Cardiology–American Heart Association; NYHA ¼ New York Heart AsMOGE(S) Nomenclature for HCM
HCM phenotypically denotes a heterogeneous group of
syndromes all sharing a cardiac trait of thickening of the LV
wall; the 2 major groups include sarcomeric (up to 90% of all
HCM caused by mutations of structural and regulatory
genes of the sarcomere) and nonsarcomeric HCM (Table 1).
The diagnosis of sarcomeric HCM implies that a sarco-
meric gene defect has been identiﬁed, and the mutation is
duly noted in the etiological (E) annotation, such as MH OH
GAD EG-MYH7[p.Arg403Glu]. Although earlier studies attemp-
ted to correlate distinct gene defects with the severity of the
disease, little has been conﬁrmed after 20 years of genotype
to phenotype correlation studies (39). Several disease genes
have been identiﬁed; defects ofMYH7andMYBPC3 account
for up to 70% of sarcomeric HCM, followed by troponin
gene defects (TNNI3, TNNT2) and other less commonly
involved genes (ACTC1, CSRP3, CRYAB, CAV3, MYH6,
MYL2,MYL, TNNC1, TCAP,MYOZ1,MYOZ2) (Table 1).
The extracardiac markers are conspicuously absent in auto-
somal dominant sarcomeric HCM. A minority of sarcomeric
HCM may show associated myopathy, a feature that may be
described as MH OHþM GAD EG-MYH7[p.Arg403Glu].Provided in the Lower Part of the Table
E
Etiological Annotationx
S
Stage; ACC/AHA Stage,
NYHA Functional Classk
netic etiologydadd gene and mutation; (NC)
vidual noncarrier plus the gene that tested
ative
bligate carrier
Obligate noncarrier
e novo
mplex genetics when >1 mutation
vide additional gene and mutation)
Genetic test negative for the known familial
ation
enetic test not yet available
netic defect not identiﬁed
genetic test, any reason (no blood sample, no
rmed consent, etc.)
c amyloidosis (A-TTR) or
ochromatosis (HFE)
netic etiologies:
ocarditis
l infection (add the virus identiﬁed in affected
rt)
toimmune/immune-mediated; suspected
), proven (AI-P);
yloidosis (add type of amyloidosis:
A-L, A-SAA)
ctious, nonviral (add the infectious agent)
icity (add toxic cause/drug)
ypereosinophilic heart disease
ACC/AHA stage represented as
letter (A, B, C, D)
To be followed by NYHA functional
class represented in Roman
numerals (I, II, III, IV)
YH7[R403E], EG-HFE[Cys282Tyrþ/þ],
CMV, EG-A-TTR[V30M], EM-sarcoidosis
SA-I, SA-II
bbreviations, such as AVB ¼ atrioventricular block; WPW ¼ Wolff-Parkinson-White syndrome;
R ¼ short PR interval. yOrgan (O) involvement in addition to the H subscript (for heart) should be
kidney, L ¼ liver, N ¼ nervous system, C ¼ cutaneous, G ¼ gastrointestinal system, and other
inheritance of the disease. It also provides complete information if the family history is not proven or
tiﬁed in the family. xThe etiologic annotation (E) provides the facility for the synthetic description of
nnotation or staging (S) allows the addition of ACC/AHA stage and NYHA functional class.
sociation; other abbreviations as in Table 1.
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2062Autosomal recessive HCM is rare (40): these families differ
from those in which double or triple mutations are identiﬁed
but inheritance is autosomal dominant. In fact, an increas-
ingly greater proportion of patients with sarcomeric HCM
are being recognized with double and compound mutations
contributing to worse phenotype and high arrhythmogenic
risk regardless of the ventricular wall thickness; double (or
compound) mutations detected by genetic testing may confer
a genedose effect in HCM (such as MH OH GAD EG-MYH7
[p.Arg403Glu]þMYBPC3[IVS7þ1G>A]) and may predispose patients
to adverse disease progression (41,42). Some examples of
MOGE(S) nomenclature for sarcomeric HCM are pre-
sented below.
MH OH GAD EG-MYH7[p. Arg403Glu] SB-I represents:
morphofunctional phenotype (M): hypertrophic (H) car-
diomyopathy; organ (O) involvement: heart (H); genetic/
familial (G) with autosomal dominant (AD) transmission;
etiology (E): genetic (G) and caused by the p.Arg403Glu
mutation of the MYH7 gene, ACC/AHA stage (S) B,
NYHA I.
ME(H) OH GAD EG-MYH7[p. Arg403Glu] SA-I represents
morphofunctional phenotype (M): “early” (E) hypertrophic
(H) cardiomyopathy (for example, borderline LV thickness
or early diastolic dysfunction or electrocardiographic (ECG)
abnormalities suggesting hypertrophy with normal LV
thickness); organ (O) involvement: heart (H); genetic/
familial (G) with autosomal dominant (AD) transmission;
etiology (E): genetic (G) and caused by the p.Arg403Glu
mutation of the MYH7 gene; ACC/AHA stage (S) A,
NYHA I.
ME(H) OH GAD EG-NA SA-I represents: morphofunc-
tional phenotype (M): “early” (E) hypertrophic (H) cardio-
myopathy organ (O) involvement: heart (H); genetic/
familial (G) with autosomal dominant (AD) transmission;
etiology (E): genetic but the mutation is not yet available
(NA) (either ongoing or to be done but feasible); ACC/AHA
stage (S) A, NYHA I.
M0 O0 GAD EG-MYH7[p. Arg403Glu] SA-I represents: mor-
phofunctional phenotype (M): “unaffected” (0) by cardio-
myopathy; organ (O) involvement: absence of any cardiac
phenotype (zero, 0); in familial/genetic (G) autosomal
dominant (AD) cardiomyopathy; etiology (E) genetic (G),
healthy carrier of the p.Arg403Glu mutation of the MYH7
gene that causes the disease in the family; ACC/AHA stage
(S) A, NYHA I.
Because the intrafamily variability of the phenotype
may include different morphofunctional phenotypes (for
example, HCM and DCM, the latter often representing the
end-stage evolution of the original hypertrophic phenotype),
a combination of morphofunctional phenotypes is possible
(HDD).
Nonsarcomeric HCM may show different types of inheri-
tance, such as AD in PRKAG2-related HCM with WPW
(43), AR in Friedrich ataxia (44), X-linked in Danon disease
(45) and inAndersonFabry disease (AFD) (46), AR inPompe
disease (47), or matrilineal (or maternal) in cardiomyopathiescaused bymutations in themitochondrial DNA (48) (Table 3,
Fig. 5). Mitochondrial diseases constitute a large and hetero-
geneous group of complex diseases/syndromes (1 per 4,000 to
5,000 live births) caused by mutations of nuclear (inherited
according to Mendelian rules) or mitochondrial (matrilineal
inheritancewith absence ofmale transmission) genes (Table 4)
(49–56). Cardiologists encounter mitochondrial diseases in
their routine practice either in patients presenting with HCM
or DCM, or in patients referred by neurologists or myologists
for consultation. The role of the cardiologists is essential for
suspecting a mitochondrial disease in patients with cardio-
myopathy at onset or as ﬁrst clinical manifestation. Mito-
chondrial HCM initially shows symmetrical LV hypertrophy,
and subsequently evolves through LV dysfunction and dila-
tion. A number of cardiac (short PR interval, pre-excitation
syndrome, AVB) or noncardiac (hearing loss, myopathy,
palpebral ptosis, nonvascular neurological involvement,mental
retardation) markers, or biochemical (elevated serum creatine
phosphokinase [[sCPK], lactacidemia) indicators in probands
and relatives provide diagnostic clues (35).
The MOGE(S) system allows a comprehensive summary
of the clinical and genetic status of the family once the
diagnosis has been made and family screening completed.
The availability of the functional status (S) becomes espe-
cially important in asymptomatic relatives with manifest
causative gene defect. Both cardiac and extracardiac traits
contribute to clinical recognition of genotypes (Table 4) (35)
(Fig. 7). A systematic approach leads to better character-
ization of cardiomyopathic disorder and could identify the
need for pathological conﬁrmation of the etiological basis of
the disease, such as in AFD (Fig. 6). An accurate diagnosis
is mandatory for genetic counseling and disease manage-
ment; for example, the availability of enzyme replacement
therapy in AFD may change the natural history of the
disease and prevent (or delay) the end-stage disease.
MOGE(S) Nomenclature for RCM
RCM is clinically characterized by altered relaxation and
abnormal LV ﬁlling, biatrial dilation, in the absence of
signiﬁcant LV hypertrophy (Table 2). The lack of hyper-
trophy distinguishes RCM from HCM with restrictive
pattern. Troponinopathies and desminopathies are typical
examples of pure RCM; the former is not associated with
conduction disease, whereas the latter is associated with
AVB. Troponinopathies are encountered as de novo or
inherited as an AD disease, whereas the desminopathies are
inherited as AD (50%), AR (25%), or de novo (25%)
(57,58). The differential diagnosis of desminopathy is based
on the presence of AVB and its association with myopathy;
a ﬁne-needle biopsy of the skeletal muscle immunostained
with anti-desmin antibodies may provide the ﬁnal diagnosis
(Fig. 8). Alternatively, endomyocardial biopsy may demon-
strate intracellular osmiophilic granuloﬁlamentous inclusions
that immunoreact with anti-desmin antibodies. Pure RCM
due to defects of troponin genes, TNNI3 in particular, may
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presence of myocyte disarray otherwise characteristic of
sarcomeropathy (59). The clinical distinction of the tropo-
ninopathy (60,61) and desminopathy is important because of
the high arrhythmogenic risk in troponinopathy and the
negligible risk in desminopathy. In a recent meta-analysis
including desmin-related diseases, both myopathies and
cardiomyopathies, sudden death was reported in 2 of 195
DES mutation carriers (62). On the other hand, desmin-
opathy shows high risk of AVB. Both entities share a very
high penetrance, and almost all mutated individuals
demonstrate manifest disease by the age of 40 years (63).
MOGE(S) applies to RCM as follows.
MR[AVB] OHDM GAD EG-Des[p.Gly84Ser] SC-III represents
morphofunctional phenotype (M): restrictive cardiomyop-
athy (R) with AVB; organ (O) involvement: heart (H) and
skeletal muscle (M); genetic/familial (G) with autosomal
dominant (AD) transmission; etiology (E): genetic (G)
caused by the p.Gly84Ser mutation in the Desmin gene;
ACC/AHA stage (S) C, NYHA III.
ME(R) [AVB] OHDM GAD EG-Des[p.Gly84Ser] SA-I repre-
sents morphofunctional phenotype (M): “early” (E) restric-
tive cardiomyopathy with AVB; organ (O) involvement:
heart (H) and skeletal muscle (M); genetic/familial (G) with
autosomal dominant (AD) transmission; etiology (E): genetic
(G) caused by the p.Gly84Ser in the Desmin gene; ACC/
AHA stage (S) A, NYHA I.
M0 O0 GAD EG-Des[p.Gly84Ser] SA-I represents morpho-
functional phenotype (M): “unaffected” (0) by cardiomyop-
athy; organ (O) involvement: none (¼absence of any cardiac
phenotype); genetic/familial (G) with autosomal dominant
(AD) transmission; etiology (E): genetic and caused by the
p.Gly84Ser mutation in the Desmin gene; ACC/AHA stage
(S) A, NYHA I.
MOGE(S) Classiﬁcation for Amyloid Heart Disease
Amyloidosis represents a distinct and unique condition of
extracellular inﬁltrative disease. Most cardioamyloidoses are
in the context of systemic diseases (genetic or nongenetic).
Its inclusion in MOGE(S) is supported by the cardiac
phenotype and clinical presentation as HCM or RCM that
must be distinguished from other HCM and RCM.
Amyloid shows distinct staining properties (pink-violet color
with hematoxylin and eosin, apple-green birefringence with
Congo Red under polarized light, and magenta color with
crystal violet) and ultrastructural characteristics (ﬁbrils of
7.5- to 10-nm diameter), regardless of the amyloidogenic
protein (64,65). Amyloidosis may be systemic or localized,
the former including primary (AL), secondary (AA), and
genetic (multiple and different genes) forms. The heart
shows inﬁltration in the interstitial spaces, vessel walls of
epicardial coronary arteries and intramural small vessels,
cardiac valves, and epicardial fat (66). The heart is usually
hypertrophied, with thickened cardiac valves, and showsa restrictive functional pattern. The typical patient is an adult
or an old individual of either sex with a long-standing
history of nonspeciﬁc symptoms; family history is positive
for heart failure, renal or multiorgan failure in heritable
forms. The children with familial Mediterranean fever
caused by mutations of the gene Marenostrin (MEFV) may
show amyloidosis of kidney, skin, thyroid; the heart is less
likely to be involved (67).
In most cases of cardiac amyloidosis, there is an echo-
ECG mismatch with increased LV wall thickness and
decreased ECG voltages. The amyloidogenic protein can
be identiﬁed by immunoelectron microscopy study of the
endomyocardial biopsy (or the peri-umbilical fat in systemic
forms). The genetic testing is mandatory in familial
amyloidosis (68,69); the investigation of the family members
not only may provide early or pre-clinical diagnosis, but also
contributes to understanding the natural history of the
disease. The MOGE(S) system facilitates the description of
the amyloid cardiomyopathy. MOGE(S) applies to cardiac
amyloidosis as follows.
MHDR( ECG voltages) OHDK GN EA-L SB-II represents
morphofunctional phenotype (M): hypertrophic cardiomy-
opathy with restrictive pattern (HþR), low ECG voltages;
organ (O) involvement: heart (H) and kidney (K); genetic/
familial (G): negative family history (N) (and/or screening);
etiology (E): amyloidosis (A), amyloidogenic light chain
lambda (L); ACC/AHA stage (S) B, NYHA II.
MOGE(S) Nomenclature for DCM
DCM is characterized by the presence of LV dilation and
LV systolic dysfunction in the absence of other disorders
sufﬁcient to cause global systolic impairment (Table 2).
Right ventricular dilation and dysfunction can be present,
but not necessary, for the diagnosis (8). More than 50% of
the DCM cases are familial (10). Although all DCM
phenotypically look alike, most of them are distinct genetic
diseases. Mutations in more than 40 genes have been
described (Table 1), leading to extreme genetic heteroge-
neity (70). Most familial DCMs are AD, and a minority is
X-linked recessive, autosomal recessive, or matrilineal (10).
The most common disease gene is Lamin A/C, and the
laminopathy constitutes 8% of all DCMs (66). Dystrophin
gene defects account for up to 7% of male patients with
DCM; most of these patients show an increase in sCPK
without apparent myopathy (16,71,72) (Fig. 9). About one-
fourth of the DCM cases have been recently attributed to
the mutations in the giant Titin (TTN) gene (73). The
elastic protein titin is expressed in cardiomyocytes in 2 main
isoforms, N2B (stiffer spring) and N2BA (more compliant
spring). Titin-isoform switching is considered a mechanism
for increased myocardial passive stiffness found in patients
with heart failure with preserved LVEF (74). While waiting
for conﬁrmatory studies, Titin remains an important disease
gene. DCM patients with TTN mutations do not show
disease-speciﬁc clinical markers (73). The laminopathies are
Table 3 Major Mutations in MTDNA* and Nuclear Genes and Cardiac Phenotypes Reported to Date
MTDNA Disease Allele Gene HCM DCM RCM LVNC
MTTL1 MMC/MELAS A3260G tRNALeu(UUR) X X
MTTL1 MMC C3303T tRNALeu(UUR) X X
MTTL1 MELAS A3243G tRNALeu(UUR) X X X X
MTTL1 MELAS G3244A tRNALeu(UUR) X
MTTL1 MM/HCM þ RENAL TUBULAR
DYSFUNCTION
G3242A tRNALeu(UUR) X X
MTTL1 MELAS A3252G tRNALeu(UUR) X
MTTL1 MELAS/myopathy T3258C tRNALeu(UUR) X X
MTTL1 Myopathy A3280G tRNALeu(UUR) X X
MTTL2 DCM/LS/failure to thrive and LA T12297C tRNALeu(CUN) X
MTTI MHCM A4295G tRNAIle X X
MTTI MICM A4300G tRNAIle X X
MTTI FICP A4269G tRNAIle X X
MTTI HCM with hearing loss/possible
hypertension factor
A4316G tRNAIle X
MTTI FICP A4317G tRNAIle X X
MTTI Varied familial presentation/spastic
paraparesis
G4284A tRNAIle X X
MTTI Mitochondrial encephalocardiomyopathy C4320T tRNAIle X X
MTTK Cardiomyopathy/SNHL A8348G tRNALys X X
MTTK MERRF A8344G tRNALys X X
MTTK MERRF/MICMþDEAF/autism/LS G8363A tRNALys X X
MTTG MHCM T9997C tRNAGly X
MTTH MICM G12192A tRNAHis X
MTTP DCM T16032TTCTCTGTTCTTTCAT
(15 bp dup)
tRNAPro X
MTTQ Possibly LVNC-associated T4373C tRNA Gln X
MTTV LS C1624T tRNAVal X X
MTTV Adult LS G1644T tRNAVal X
MTRNR2 MELAS C3093G 16S rRNA X
MTRNR1 Possibly LVNC-associated T921C 12S rRNA X
MTRNR1 Possibly LVNC-associated T850C 12S rRNA X
MTRNR1 DEAF, possibly LVNC-associated T961C 12S rRNA X
MTRNR1 Found in 1 HCM patient T1391C 12S rRNA X
MTRNR1 Found in 1 HCM patient C1556T 12S rRNA X
MTRNR2 Possibly LVNC-associated T2352C 16S rRNA X
MTRNR2 Possibly LVNC-associated G2361A 16S rRNA X
MTRNR2 Possibly LVNC-associated A2755G 16S rRNA X
MTCYB HCM G15243A (G166E) MTCYB X
MTCYB HCM/WPW,DEAF G15498A (G251D) MTCYB X
MTCO1 Idiopathic sideroblastic anemia T6721C (M273T) MTCO1 X
MTCO1 Idiopathic sideroblastic anemia T6742C (I280T) MTCO1 X
MTND4 Diabetes mellitus A12026G (I423V) MTND4 X
Continued on the next page
Arbustini et al. JACC Vol. 62, No. 22, 2013
The MOGE(S) Classification December 3, 2013:2046–72
2064clinically characterized by conduction tissue disease in up to
80% of patients; the remaining patients demonstrate atrial
ﬁbrillation or an ARVC-like phenotype (75). Dystrophin-
opathy is associated with severely enlarged and dysfunctional
ventricles, and increased sCPK (16,72). Zaspopathies (76)
and tafazzinopathies show either LVNC or increased tra-
beculations in the setting of DCM (77); the tafazzinopathies
typically occur in infancy and characteristically show cyclic
neutropenia, oral aphthous ulcers, and hypocholesterolemia
(77). A small number of DCM patients are characterized byautosomal recessive inheritance and are usually brought to
the attention of cardiologists when being evaluated for lipid
storage disease in a multidisciplinary context. Table 5
summarizes the known disease genes as well as the cardiac
phenotypes typically expressed in these disorders (78–83).
Cardiomyopathy, mostly DCM, is one of the common traits
recurring in these syndromes, and in some of them it may be
the sole manifestation of the disease (79,84,85).
All aforesaid information, including the common cardiac
phenotype, the clinical markers, or red ﬂags that may occur
Nuclear
Genes Phenotype Inheritance HCM DCM RCM LVNC
ANT1 (PEOA2) AD-PEO, multiple mtDNA deletions AD X X
AGK Sengers syndrome (HCM, cataract and myopathy) AR X
COX10 Neonatal tubulopathy and encephalopathy, LS AR X
COX15 Early-onset HCM, LS AR X
DNAJC19 DCM and LVNC, early onset, anemia, ataxia, male genital anomalies and
methylglutaconic aciduria type V
AR X X
FRDA Friedreich ataxia, neuropathy, cardiomyopathy, diabetes AR X X
G4.5 (Tafazzin) Barth syndrome, X-linked dilated cardiomyopathy X-linked X X
MFN2 Charcot-Marie-Tooth disease type 2A2 AD X
POLG (PEOA1) Alpers syndrome, AD-PEO and AR-PEO, male infertility,
SANDO syndrome, SCAE
AD-AR X X
NDUFS2 Encephalopathy AR X X
NDUFV2 Hypotonia, encephalopathy AR X
SCO2 Neonatal cardio-encephalomyopathy AR X X
*http://www.mitomap.org; last accessed November 6, 2013. Short PR electrocardiogram intervals and pre-excitation recur in mitochondrial cardiac phenotypes, especially in the early phases of the disease.
Atrioventricular block is more common in late phases of the disease.
DEAF ¼ maternally inherited deafness or aminoglycoside-induced deafness; FICP ¼ fatal infantile cardiomyopathy plus, a MELAS-associated cardiomyopathy; LD ¼ Leigh disease; LS ¼ Leigh
syndrome; LA ¼ Lactic Acidosis; LVNC ¼ left ventricular noncompaction; MELAS ¼ mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes; MERRF ¼ myoclonic epilepsy and ragged
red muscle ﬁbers; MHCM ¼ maternally inherited hypertrophic cardiomyopathy; MICM ¼ maternally inherited cardiomyopathy; MMC ¼ maternal myopathy and cardiomyopathy; mtDNA ¼ mitochondrial
DNA; PEO ¼ progressive external ophthalmoplegia; SANDO ¼ sensory ataxic neuropathy with dysarthria/dysphagia and ophthalmoplegia; SCAE ¼ spinocerebellar ataxia with epilepsy; other abbreviations
as in Table 1.
Table 3 Continued
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2065in patients/carriers of mutations of the same gene, are
systematically organized in the MOGE(S) system, thus
generating a common pheno-molecular language that can be
easily adopted by clinicians in their daily practice, without
the risk of missing out on any necessary information.
MOGE(S) applies to DCM as follows.
MD[AVB] OH GAD EG-LMNA[p.Leu197ProfsX2] SC-II repre-
sents morphofunctional phenotype (M): dilated cardiomy-
opathy with atrioventricular block; organ (O) involvement:
heart (H); genetic/familial (G) with autosomal dominant
(AD) transmission; etiology (E): genetic and caused by the
p.Leu197Pro fs X2 mutation in the LMNA gene; ACC/
AHA stage (S) C, NYHA II.
ME(D) OH GAD EG-LMNA[p. Leu197ProfsX2] SA-I represents
morphofunctional phenotype (M): “early” (E) dilated
cardiomyopathy (for example, increased LV end-diastolic
dimension with normal LV function, or borderline LV
function); organ (O) involvement: heart (H); genetic/
familial (G) with autosomal dominant (AD) transmission;
etiology (E) is genetic and caused by the p.Leu197Pro fs X2
mutation in the LMNA gene; ACC/AHA stage (S) A,
NYHA I.
ME(D) OHGAD EG-NA SA-I represents morphofunctional
phenotype (M): “early” (E) dilated cardiomyopathy (see
example in the preceding text); organ (O) involvement: heart
(H); genetic/familial (G) with autosomal dominant (AD)
transmission; etiology (E): genetic but the mutations is not
yet available (NA) (genetic test either ongoing or to be done,
but feasible); ACC/AHA stage (S) A, NYHA I.
M0 O0 GAD EG-LMNA[p. Leu197ProfsX2] SA-I represents
morphofunctional phenotype (M): “unaffected” (0) by
cardiomyopathy; organ (O) involvement: none (0) (¼
absence of any cardiac phenotype); genetic/familial (G) with
autosomal dominant (AD) transmission; etiology (E): genetic(G), healthy carrier of the p.Leu197Pro fs X2 mutation in
the LMNA gene that causes the disease in the family; ACC/
AHA stage (S) A, NYHA I.
The genetic testing in future is expected to inﬂuence
clinical decision making for primary prevention of sudden
death and ICD implantation. In the current guidelines the
severely depressed LVEF constitutes the major indication
for ICD implantation in patients with DCM (11–13). It is
now becoming increasingly evident that laminopathies carry
high arrhythmogenic risk (15,20) even when they may not
meet guideline recommendations for ICD implantation. On
the other hand, some genes and genetic variants may not be
at high risk even though they may result in low LVEF (16).
A group of DCM caused by mutations in genes typically
related to ARVC have a high risk of life-threatening
arrhythmias and may deserve ICD implantation even if
they fall short of guideline-based recommendations (11–13).
As we accumulate more knowledge and experience, the
indications for ICD implantation will be modiﬁed, made
more speciﬁc, and personalized.
MOGE(S) Nomenclature for ARVC
Although predominantly affecting the RV, the spectrum of
ARVC now includes possible biventricular involvement as
well as the left dominant arrhythmogenic cardiomyopathy
(86), referred to as arrhythmogenic cardiomyopathy (ACM)/
ARVC in the recent HRS/EHRA Expert Consensus
Statement on the State of Genetic Testing for the Channe-
lopathies and Cardiomyopathies (87). Although all ACM/
ARVC phenotypes are associated with mutations in
desmosome genes (88,89), mutations in typically DCM-
related genes have also been observed in ARVC-like
phenotypes (75). The practical implication of such
Table 4 Most Common Metabolic Diseases Causing Cardiomyopathy Phenocopies and Synthetic Description of Involvements of Other Organs/Tissues
Disease
MIM #
Phenotype Inheritance Age of Onset
Disease
Gene Cardiac Phenotype
Extracardiac Markers/Major Involvement
(Noncomprehensive) of Other Organs
Speciﬁc
Treatment
Glycogen storage disease (GSD)
GSDII (Pompe disease, glycogen
storage disease II, acid
alpha-glucosidase/acid maltase
deﬁciency)
232300 AR Infant to young adult GAA HCM Skeletal muscle, liver ERT (gene
therapy;
substrate
reduction
therapy)
GSDIII (Forbes or Cori disease,
glycogen debranching enzyme)
232400 AR Childhood AGL HCM Liver, skeletal muscle, hypoglycemia,
growth retardation
GSD IV (Anderson disease, glycogen
branching enzyme)
232500 AR Perinatal, congenital, infant,
childhood, adult
GBE1 DCM Liver, skeletal muscle, brain
GSD V (McArdle disease, glycogen
phosphorylase)
232600 AR Young adult PYGM DCM Skeletal muscle; myoglobinuria
GSD 0 (muscle) (muscle glycogen
synthase
611556 AR Childhood GYS1 HCM Skeletal muscle
Other disorders of the glycogen metabolism
PRKAG2-related disease
Lethal congenital glycogen storage
disease of heart
261740 AD Young adult PRKAG2 HCM d
PRKAG2-related familial hypertrophic
cardiomyopathy
600858 AD Young adult PRKAG2 HCM d
Wolff-Parkinson-White syndrome 194200 AD Young adult PRKAG2 WPW with/without HCM d
Danon disease (lysosomal-associated
membrane protein 2)
300257 XL Childhood in males, young adult in
females
LAMP2 HCM, HCM evolving
through dilation and
dysfunction, LVNC
Skeletal muscle, cognitive impairment in
males, pigmentary retinopathy also in
females
Lysosomal storage diseases: sphingolipidoses
Anderson-Fabry disease (alpha-
galactosidase deﬁciency)
301500 XL Childhood to adulthood GLA Symmetrical HCM Renal, ocular, nervous, cutaneous,
gastrointestinal systems
ERT
Anderson-Fabry diseasedlater onset,
cardiac variant
301500 XL Adult GLA HCM d ERT
GM1 gangliosidosis (beta-
galactosidase deﬁciency)
230500 AR Infancy (infantile form), childhood
(late-infantile/juvenile form), adult
(chronic form)
GLB1 HCM, DCM Neurological and skeletal systems,
hepatosplenomegaly
MLD (Metachromatic leucodystrophy) 250100 AD Infancy (infantile form), childhood
(juvenile form), adult (adult form)
ARSA RCM/DCM Skeletal muscle, nervous, ocular systems
GM1 gangliosidosis with cardiac
involvement (beta-galactosidase
deﬁciency) (50–53)
230500 AR Infancy (infantile form), childhood
(juvenile form), adult (adult form)
GLB1 HCM/DCM, mitral valve
thickening, CAD
Skeletal muscle, nervous, renal, ocular,
and cutaneous systems
GM2 gangliosidosis (Tay-Sachs
disease)
272800 AR Infancy (infantile form), childhood
(juvenile form), adult (adult form)
HEXA Valve disease Nervous, ocular, auditory
GM2 gangliosidosis
(Sandhoff-Jatzkewitz
disease) (54,55)
268800 AR Infancy (infantile form), childhood
(juvenile form), adult (adult form)
HEXB HCM, Mitral and aortic
valve disease
Nervous, skeletal muscle, ocular systems
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Table 4 Continued
Disease
MIM #
Phenotype Inheritance Age of Onset
Disease
Gene Cardiac Phenotype
Extracardiac Markers/Major Involvement
(Noncomprehensive) of Other Organs
Speciﬁc
Treatment
Gaucher disease (glucocerebrosidase
deﬁciency), types I, II and III,
perinatal lethal and type IIIC with
cardiovascular calciﬁcations
(cardiac variant)
230800 AR Childhood to young adult GBA (HK
gene)
Cardiovascular
calciﬁcations
Hemopoietic, nervous, bone, cutaneous
systems, hepatosplenomegaly
ERT
Niemann-Pick disease
(types C1, D) (56)
257220 AR Infant, childhood, adult NPC1 Coronary artery and
valvular heart disease
Nervous, bone, cutaneous systems,
hepatosplenomegaly, sea-blue
histiocytes
Lysosomal storage diseases: mucopolysaccaridoses (degradation defects of glycosaminoglycans)
MPS I (Hurler and Scheie syndromes)
(iduronidase enzyme deﬁciency)
607014,
607016,
607015
AR Childhood to young adult DUA HCM Nervous, skeletal and joints, ocular,
cutaneous, respiratory systems
ERT
MPS II (Hunter syndrome) 309900 XLR Late infancy to young adult IDS HCM Nervous, skeletal, ocular, cutaneous,
auditory systems
ERT
MPS III A (Sanﬁlippo syndrome A) 252900 AR Infancy to young adult SGSH HCM, HF Nervous, skeletal, cutaneous systems;
abundant and coarse, often blond hair
MPS III B (Sanﬁlippo syndrome B) 252920 AR NAGLU HCM, HF Nervous; skeletal, ocular, auditory
MPS III C (Sanﬁlippo syndrome C) 252930 AR HGSNAT HCM, HF Nervous, skeletal, ocular, hypertrichosis
MPS III D (Sanﬁlippo syndrome D) 252940 AR GNS HCM, HF Nervous, skeletal, ocular, auditory,
hypertrichosis
MPS IV A (Morquio syndrome A) 253000 AR Infancy to young adult GALNS Nervous, skeletal, ocular
MPS IV B (Morquio syndrome B) 253010 AR Infancy to young adult GLB1 HCM Nervous, skeletal, ocular
MPS VI (Maroteux-Lamy syndrome) 253200 AR Infancy to adult ARSB DCM Skeletal, integumental, ocular, muscular,
hepatosplenomegaly
ERT
MPS VII (Sly syndrome) 253220 AR Infancy to adult GUSB HCM Skeletal, nervous, possible
hepatomegaly and mild ocular
MPS IX 601492 AR Infancy to young adult HYAL1 Heart involvement, NOS Skeletal, nervous, ocular
Lysosomal storage diseases: disorders of glycoprotein and glycosylation metabolism
Galactosialidosis or Goldberg
syndrome (cathepsin A defect)
256540 AR Infancy (early and late infantile types),
childhood, adult (juvenile/adult type)
CTSA HCM in late infantile type,
DCM
Nervous, skeletal, ocular, cutaneous,
auditory systems; possible
hepatosplenomegaly
Mucolipidosis or sialidosis, type I and II 256550 AR Infancy to adult NEU1 DCM Nervous, skeletal, ocular, cutaneous
systems
Fucosidosis 230000 AR Infancy to adult FUCA1 DCM, HF Nervous, skeletal, ocular, cutaneous
(angiokeratoma) systems
Alpha-mannosidosis 248500 AR Infancy to young adult MAN2B1 Possible heart
involvement, NOS
Nervous, skeletal, cutaneous, auditory
Beta-mannosidosis 248510 AR Infancy to young adult MANBA Possible heart
involvement, NOS
Nervous, skeletal, auditory, cutaneous
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2068genotype-phenotype correlative studies would be to deter-
mine whether the arrhythmogenic risk is better associated
with the disease gene or the clinical phenotype. MOGE(S)
applies to ARVC/ACM as follows.
MA[ε] OH GAD EG-DSG2[p.Glu1020AlafsX18] SA-I represents
morphofunctional phenotype (M): ARVC with ε wave;
organ (O) involvement: heart (H); genetic/familial (G) with
autosomal dominant (AD) transmission; etiology (E): genetic
(G) and caused by the p.Glu1020Ala fs X 18 mutation in the
DSG2 gene; ACC/AHA stage (S) A, NYHA I.
ME(A) OH GAD EG-DSG2[p.Glu1020AlafsX18] SA-I represents
morphofunctional phenotype (M): “early” (E) arrhythmo-
genic cardiomyopathy (for example, with minor ECG and/or
echocardiographic criteria); organ (O) involvement: heart
(H); genetic/familial (G) with autosomal dominant (AD)
transmission; etiology (E): genetic (G) and caused by the
p.Glu1020Ala fs X 18 mutation in the DSG2 gene that
causes the disease in the family; ACC/AHA stage (S) A,
NYHA I.
M0 O0 GAD EG-DSG2[p.Glu1020AlafsX18] SA-I represents
morphofunctional phenotype (M): “unaffected” (0) by
cardiomyopathy; organ (O) involvement: none (0) (¼absence
of any cardiac phenotype); genetic/familial (G) with auto-
somal dominant (AD) transmission; etiology (E): genetic (G),
healthy carrier of the p.Glu1020Ala fs X 18 mutation in the
DSG2 gene that causes the disease in the family; ACC/
AHA stage (S) A, NYHA I.
MOGE(S) Nomenclature for LVNC
Left ventricular noncompaction (LVNC) is a morphological
entity characterized by an excessive trabeculation of the LV
(90,91) (Table 2). Diagnostic criteria are based on echo
and cardiac magnetic resonance imaging wherein the non-
compacted ventricular muscle layer is substantially thicker
than the compact layer (91). Most LVNC patients are
asymptomatic, and the diagnosis is often incidental. The
LVNC can occur as isolated morphological phenotype (92)
in association with LV systolic dysfunction or with LV
hypertrophy. LVNC has been associated with both DCM
and HCM, and with mutations in genes typically causing
DCM and HCM (93). LVNC is a typical trait in Barth
syndrome (94) (Fig. 10), and it has been reported to occur
more frequently in carriers of LDB3 gene mutations.
Although true LVNC is rare, hypertrabeculation of the LV
is common and may be associated with increased throm-
boembolic risk. The MOGE(S) system distinguishes
LVNC with LV dilation and dysfunction (MLVNCþD) or
with LV hypertrophy (MLVNCþH) from pure LVNC
(MLVNC).
The MOGE(S) Classiﬁcation in Clinical Practice
The MOGE(S) system proposes a nosology that addresses
5 simple attributes of cardiomyopathies, including mor-
phofunctional characteristic (M), organ involvement (O),
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2069genetic or familial inheritance pattern (G), and an explicit
etiological annotation (E) with details of genetic defect or
underlying disease/cause, followed by optional information
about the functional status (S) using the ACC/AHA stage
and NYHA functional class. Although the application of
this nosology allows complete description of the diseases, the
full notation may appear complex. It is expected that routine
nomenclature will continue to be described by the standard,
currently practiced morphology, and the proposed nosology
is not meant to replace the morphological description. A
dilated cardiomyopathy will be called dilated cardiomyopathy,
but the complete description of the disease process would
be best served by the descriptive terminology such as
MOGE(S). In fact, AHA suggests genotyping to supersede
the phenotypic description, which is opposed by the ESC;
the proposed MOGE(S) system is a compromise. It is
prudent to consider an example from the ﬁeld of oncology.
Pathological staging in a patient with lung cancer who has
been treated with neoadjuvant therapy and still has multiple
residual nodules in the ipsilateral lung and different lobes,
has distant metastases, and lymph nodes show isolated tumor
cells only, is described using TNM staging as follows:
ypT4(m) N0 (iþ) M1b G3 LVI þ R2. y denotes that the
patient has received neoadjuvant therapy prior to resection,
p presents pathological stage after resection, T4 offers the
extent of tumor which in this case has multiple residual
tumor nodules (m) in different lobes of ipsilateral lung,
N denotes the nodal status [N0(iþ)] isolated tumor cells
only in a lymph node that are considered node negative or
N0, and M represents metastases where M1b means distant
metastases (in contrast to M1a, which is thoracic metastases
such as contralateral lung, pleural nodules or malignant pleural,
or pericardial effusion). G in this staging is histological
grade (1 ¼ well differentiated; 2 ¼ moderate; 3 ¼ poorly
differentiated), LVI þ represents lymphovascular invasion
(LVI, absent), and R is residual disease after treatment
(R0 ¼ no residual disease; R1 ¼ microscopic residual disease;
R2 ¼ grossly identiﬁed residual disease). Howsoever complex
it may sound, oncologists are expected to use standard
TNM staging. TNM nosology is constantly expanding, is very
ﬂexible, but ensures completeness. Simply looking at
[ypT4(m) N0(iþ) M1b G3 LVIþ R2] gives physicians all the
information about the patient in question. However, in
the common practice, this patient is considered to have lung
cancer. Therefore, the MOGE(S) example MD[AVB] OH GAD
EG-LMNA[p.Arg190Trp] is complete notation for a patient
presenting with a speciﬁc DCM. The authors of the
MOGE(S) nomenclature have developed an easy web-
assisted application that can be conveniently used in daily
clinical practice for complete and descriptive classiﬁcation
of cardiomyopathy (http://moges.biomeris.com).
Conclusions
We propose a descriptive nosology that combines morpho-
functional trait and organ/system involvement with familial
Arbustini et al. JACC Vol. 62, No. 22, 2013
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2070inheritance pattern, identiﬁed genetic defect, or other
etiologies. As with the universal TNM staging for tumors, it
is expected that this description will be improved, revised,
modiﬁed, and made more comprehensive and user friendly.
It will allow better understanding of the disease, allow easier
communication among physicians, and help develop multi-
center/multinational registries to promote research in diag-
nosis and management of cardiomyopathies.
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